Pfizer buys Swiss vaccines

Pfizer executes commercial license agreements for novel human vaccines based on the Swiss company Cytos Biotechnology's Immunodrug technology.

By Sophia Carlsson

January 5, 2009 12:00 AM

The Swiss biotechnology

company Cytos Biotechnology has announced that Pfizer has exercised its options under the exclusive global research, option and license agreement signed by the two companies in August 2008 and has taken commercial licenses for specified vaccines based on Cytos Biotechnology’s Immunodrug technology.

These vaccines incorporate

specific disease targets, which are outside the scope of Cytos

Biotechnology’s own research and development programs, and Cytos Biotechnology retains its rights to develop and manufacture vaccines against different disease targets in the same human diseases.

The event triggers payments

to Cytos Biotechnology for the execution of the commercial license agreements, and Pfizer acquires world-wide exclusive rights to develop, manufacture and commercialize the specified vaccines.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.